Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
ZBH Stock Forecast 2026-2027
$93.22
Current Price
$18.47B
Market Cap
Buy 9
Hold 17
Sell 3
Wall St Analyst Ratings
Distance to ZBH Price Targets
+39.5%
To High Target of $130.00
+7.3%
To Median Target of $100.00
-5.6%
To Low Target of $88.00
ZBH Price Momentum
-0.9%
1 Week Change
-3.3%
1 Month Change
-15.2%
1 Year Change
+3.7%
Year-to-Date Change
-18.5%
From 52W High of $114.44
+10.2%
From 52W Low of $84.59
📊 TOP ANALYST CALLS
Did ZBH Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Zimmer Biomet is one of their latest high-conviction picks.
Latest ZBH Stock Price Targets & Analyst Predictions
Based on our analysis of 40 Wall Street analysts, ZBH has a neutral consensus with a median price target of $100.00 (ranging from $88.00 to $130.00). The overall analyst rating is Buy (6.7/10). Currently trading at $93.22, the median forecast implies a 7.3% upside. This outlook is supported by 9 Buy, 17 Hold, and 3 Sell ratings.
The most optimistic forecast comes from Ed Ridley-Day at Rothschild & Co, projecting a 39.5% upside. Conversely, the most conservative target is provided by Danielle Antalffy at UBS, suggesting a 5.6% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
ZBH Analyst Ratings
9
Buy
17
Hold
3
Sell
ZBH Price Target Range
Low
$88.00
Average
$100.00
High
$130.00
Current: $93.22
Latest ZBH Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for ZBH.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Feb 12, 2026 | Barclays | Matt Miksic | Underweight | Maintains | $100.00 |
| Feb 11, 2026 | Citigroup | Joanne Wuensch | Neutral | Maintains | $98.00 |
| Feb 11, 2026 | Wells Fargo | Larry Biegelsen | Equal-Weight | Maintains | $98.00 |
| Feb 10, 2026 | BTIG | Ryan Zimmerman | Buy | Reiterates | $112.00 |
| Feb 10, 2026 | Needham | Mike Matson | Hold | Reiterates | $N/A |
| Jan 28, 2026 | UBS | Danielle Antalffy | Sell | Maintains | $86.00 |
| Jan 9, 2026 | Bernstein | Lee Hambright | Market Perform | Maintains | $99.00 |
| Jan 8, 2026 | BTIG | Ryan Zimmerman | Buy | Reiterates | $112.00 |
| Jan 5, 2026 | Evercore ISI Group | Vijay Kumar | Outperform | Upgrade | $120.00 |
| Dec 16, 2025 | Baird | Jeff Johnson | Neutral | Downgrade | $100.00 |
| Dec 11, 2025 | Citigroup | Joanne Wuensch | Neutral | Maintains | $94.00 |
| Nov 10, 2025 | Canaccord Genuity | Caitlin Roberts | Hold | Maintains | $93.00 |
| Nov 6, 2025 | RBC Capital | Shagun Singh | Outperform | Maintains | $101.00 |
| Nov 6, 2025 | JP Morgan | Robbie Marcus | Neutral | Downgrade | $100.00 |
| Nov 6, 2025 | UBS | Danielle Antalffy | Sell | Maintains | $88.00 |
| Nov 6, 2025 | Barclays | Matt Miksic | Underweight | Maintains | $104.00 |
| Nov 5, 2025 | Barclays | Matt Miksic | Underweight | Maintains | $105.00 |
| Nov 5, 2025 | BTIG | Ryan Zimmerman | Buy | Maintains | $112.00 |
| Oct 22, 2025 | Canaccord Genuity | Caitlin Roberts | Hold | Maintains | $101.00 |
| Oct 13, 2025 | BTIG | Ryan Zimmerman | Buy | Maintains | $122.00 |
Zimmer Biomet Holdings, Inc. (ZBH) Competitors
The following stocks are similar to Zimmer Biomet based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Zimmer Biomet Holdings, Inc. (ZBH) Financial Data
Zimmer Biomet Holdings, Inc. has a market capitalization of $18.47B with a P/E ratio of 26.2x. The company generates $8.23B in trailing twelve-month revenue with a 8.6% profit margin.
Revenue growth is +10.9% quarter-over-quarter, while maintaining an operating margin of +14.0% and return on equity of +5.6%.
Valuation Metrics
Market Cap
$18.47B
Enterprise Value
$25.38B
P/E Ratio
26.2x
PEG Ratio
10.4x
Price/Sales
2.2x
Growth & Margins
Revenue Growth (YoY)
+10.9%
Gross Margin
+64.7%
Operating Margin
+14.0%
Net Margin
+8.6%
EPS Growth
-41.8%
Financial Health
Cash/Price Ratio
+3.4%
Current Ratio
2.0x
Debt/Equity
62.0x
ROE
+5.6%
ROA
+3.9%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Zimmer Biomet Holdings, Inc. (ZBH) Business Model
About Zimmer Biomet Holdings, Inc.
What They Do
Global medical technology company for orthopedic products.
Business Model
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive products, generating revenue through the sales of a wide range of implants and surgical technologies. The company serves various stakeholders, including patients, surgeons, and healthcare systems, across multiple global markets.
Additional Information
With a commitment to innovation, Zimmer Biomet has pursued strategic acquisitions to enhance its product offerings. Recent advancements, such as robotic-assisted surgical systems and iodine-treated implants, position the company as a leader in the orthopedic market. Founded in 1927 and headquartered in Warsaw, Indiana, it continues to focus on improving musculoskeletal health outcomes worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
17,000
CEO
Mr. Ivan Tornos
Country
United States
IPO Year
2001
Website
www.zimmerbiomet.comZimmer Biomet Holdings, Inc. (ZBH) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
ISRG's da Vinci Gains FDA Nod for Cardiac Surgery: TAM Growth Ahead?
ISRG targets cardiac surgery as a long-term da Vinci 5 growth driver after FDA clearance, eyeing nearly 160,000 potential procedures in cleared markets vs approximately 17,000 today.
Mar 12, 2026
By Indrajit Bandyopadhyay
Analyst Blog
Why Is Zimmer (ZBH) Down 2% Since Last Earnings Report?
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Mar 12, 2026
By Zacks Equity Research
Realtime BLOG
Latest News
Quick Summary
Zimmer (ZBH) reported earnings 30 days ago; investors should monitor upcoming developments and performance indicators for future stock movements.
Why It Matters
Earnings reports can influence stock prices and investor sentiment. Upcoming developments or guidance will impact ZBH's valuation and market perception.
Source: Zacks Investment Research
Market Sentiment:
Negative
Quick Summary
Portnoy Law Firm has initiated an investigation into potential securities fraud involving Zimmer Biomet Holdings, Inc. (NYSE: ZBH) and may file a class action for investors.
Why It Matters
Zimmer Biomet may face legal challenges over potential securities fraud, which could impact stock value and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Zimmer Biomet Holdings, Inc. will present new clinical data and innovations at the AAOS 2026 Annual Meeting, with Arnold Schwarzenegger as a guest speaker.
Why It Matters
Zimmer Biomet's new data and innovations reveal market positioning and potential growth, impacting investor confidence and future stock performance.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Zimmer Biomet Holdings, Inc. has approved a quarterly cash dividend for Q1 2026, signaling continued shareholder returns.
Why It Matters
Zimmer Biomet's quarterly cash dividend approval indicates financial stability and commitment to returning value to shareholders, potentially boosting investor confidence and stock demand.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Hagens Berman is investigating Zimmer Biomet Holdings (ZBH) after a 15% stock drop and lowered revenue guidance, questioning the basis for its prior revenue assurances.
Why It Matters
Zimmer Biomet's stock drop and reduced revenue guidance raise concerns over its financial stability, prompting scrutiny that may lead to further declines and legal repercussions, affecting shareholder value.
Source: PRNewsWire
Market Sentiment:
Neutral
Biggest S&P 500 Winners Last 5, 10, 20 Years
24 days ago
Quick Summary
The S&P 500's annualized total return over the past five years is 13.5%, while the average stock in the index has returned 10.9%.
Why It Matters
The disparity between the S&P 500's total return and the average stock suggests potential overvaluation of index-heavy stocks, signaling caution for future investments.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About ZBH Stock
What is Zimmer Biomet Holdings, Inc.'s (ZBH) stock forecast for 2026?
Based on our analysis of 40 Wall Street analysts, Zimmer Biomet Holdings, Inc. (ZBH) has a median price target of $100.00. The highest price target is $130.00 and the lowest is $88.00.
Is ZBH stock a good investment in 2026?
According to current analyst ratings, ZBH has 9 Buy ratings, 17 Hold ratings, and 3 Sell ratings. The stock is currently trading at $93.22. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for ZBH stock?
Wall Street analysts predict ZBH stock could reach $100.00 in the next 12 months. This represents a 7.3% increase from the current price of $93.22. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Zimmer Biomet Holdings, Inc.'s business model?
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive products, generating revenue through the sales of a wide range of implants and surgical technologies. The company serves various stakeholders, including patients, surgeons, and healthcare systems, across multiple global markets.
What is the highest forecasted price for ZBH Zimmer Biomet Holdings, Inc.?
The highest price target for ZBH is $130.00 from Ed Ridley-Day at Rothschild & Co, which represents a 39.5% increase from the current price of $93.22.
What is the lowest forecasted price for ZBH Zimmer Biomet Holdings, Inc.?
The lowest price target for ZBH is $88.00 from Danielle Antalffy at UBS, which represents a -5.6% decrease from the current price of $93.22.
What is the overall ZBH consensus from analysts for Zimmer Biomet Holdings, Inc.?
The overall analyst consensus for ZBH is neutral. Out of 40 Wall Street analysts, 9 rate it as Buy, 17 as Hold, and 3 as Sell, with a median price target of $100.00.
How accurate are ZBH stock price projections?
Stock price projections, including those for Zimmer Biomet Holdings, Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: March 15, 2026 5:53 PM UTC